This is a PDF Þle of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its Þnal form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. rate <50 or ≥100 bpm (1 point), and systolic blood pressure <100 mmHg (2 points) was developed. Model discrimination was good in the derivation cohort (c-statistic 0.72) and temporal validation cohort (c-statistic 0.74), and calibration was reasonable with a tendency towards overestimation of risk with a higher sum of score points. External validation showed moderate discrimination (c-statistic 0.65) and calibration showed a general underestimation of predicted risk. Conclusions: A simple points score containing five variables readily available on admission predicts in-hospital CA for patients with suspected NSTE-ACS.
of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART), we identified patients (n=242 303) admitted with suspected NSTE-ACS between 2008 and 2014. Logistic regression was used to assess the association between 26 candidate variables and in-hospital CA. A risk-score model was developed and validated using a temporal cohort (n=126 073) comprising patients from SWEDEHEART between 2005 and 2007 and an external cohort (n=276 109) comprising patients from the Myocardial Ischaemia National Audit Project (MINAP) between 2008 and 2013. Results: The incidence of in-hospital CA for NSTE-ACS and non-ACS was lower in the SWEDEHEART-derivation cohort than in MINAP (1.3% and 0.5% vs. 2.3% and 2.3%). A seven point, five variable risk score (age ≥60 years (1 point), ST-T abnormalities (2 points), Killip Class >1 (1 point), heart rate <50 or ≥100 bpm (1 point), and systolic blood pressure <100 mmHg (2 points) was developed. Model discrimination was good in the derivation cohort (c-statistic 0.72) and temporal validation cohort (c-statistic 0.74), and calibration was reasonable with a tendency towards overestimation of risk with a higher sum of score points. External validation showed
Introduction
In-hospital cardiac arrest (CA) is an infrequent, but life-threatening complication of a non-ST elevation acute coronary syndrome (NSTE-ACS). The cause of in-hospital CA is usually ventricular tachycardia (VT) or ventricular fibrillation (VF), reported to occur in 1.5-2.1% of patients 1, 2 . Although less common, patients are also at risk of non-VT/VF CA 3 . There are no contemporary clinical risk scores available to estimate the risk of hospital CA using data obtained at the time of admission among patients with suspected NSTE-ACS.
Recommendations for continuous ECG-monitoring of patients admitted to hospital with suspected NSTE-ACS differ, but guidelines emphasize the importance of early risk stratification to reduce adverse clinical outcomes 4, 5 The aim of this study was to develop an easy-to-use clinical risk-score that may help the physician assess the risk of in-hospital CA and hence the need for cardiac rhythm monitoring and level of surveillance in patients admitted with suspected NSTE-ACS. For this purpose, we identified predictors of CA present at hospital admission and developed and validated a risk-score model for in-hospital CA in the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART). We externally validated the risk score in the United Kingdom Myocardial Ischaemia National Audit Project (MINAP).
Methods

Study population
The study comprised all patients admitted to a coronary care unit (CCU) with suspected or confirmed ACS and registered in SWEDEHEART. Data on clinical variables at admission, current medication, treatment and procedures during hospitalization, and final diagnoses are recorded as part of the registry. SWEDEHEART has been described in detail previously 6 . All patients are informed about collection of data in the registry and are allowed to opt-out.
SWEDEHEART is cross-linked with the Swedish National Patient Registry, to enrich data on previous medical history, and with the Swedish Population registry to obtain date of death.
The protocol of this study was approved by the regional ethics committee in Stockholm,
Sweden and was conducted complying with the Declaration of Helsinki.
Derivation cohort
All patients at least 18 years old registered in SWEDEHEART between January 1 2008 and December 31 2014 were eligible (n=353 140). Patients could be eligible for entry more than once. Exclusion criteria included ST-elevation myocardial infarction (n=40 798), CA prior to admission (n=4200), and missing data regarding CA prior to admission (n=54 864) or inhospital CA (n=13 281). In total, 242 303 cases (187 662 unique patients) remained in the study population for analyses (figure 1).
Definition of CA
In-hospital CA requiring defibrillation or cardiopulmonary resuscitation is recorded prospectively as part of SWEDEHEART. This variable is categorized as "VT/VF", "other causes of CA", or "no CA". Given that there may be overlap between the first two categories all analyses were conducted using a dichotomized variable defined as in-hospital CA "yes" or "no".
Statistical analyses
Baseline characteristics for continuous data are presented as median (interquartile range) or as numbers and proportions for categorical data.
Risk score derivation
Logistic regression was used to assess the association between in-hospital CA and baseline patient characteristics. Candidate variables were incorporated based on findings from prior studies, current NSTE-ACS guideline recommendations, clinical relevance, and availability at admission 1, 2, 4, 5, 7 . Continuous variables were divided into deciles and the most appropriate cut-offs were chosen, without testing for non-linear relationships or interactions. Backward selection was performed using a 0.05 significance level. In the final model, all included variables were dichotomized.
The following 26 variables were tested in the logistic regression models: age, gender, weight, smoking status (dichotomized as current smoker yes/no); prior diseases including hypertension, diabetes, chronic obstructive pulmonary disease, heart failure, myocardial infarction, stroke, and peripheral vascular disease; prior coronary interventions including PCI and coronary artery bypass graft (CABG) surgery; current pharmacological treatment including beta blockers, calcium antagonists, digoxin, aspirin, angiotensin-converting enzyme (ACE) inhibitors / angiotensin receptor blockers (ARB), and statins; clinical findings at presentation including Killip class, heart rate, systolic blood pressure, and electrocardiographic ST-T-changes; laboratory findings at presentation including glucose, hemoglobin, and estimated glomerular filtration rate (eGFR) based on the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula 8 . Given that only peak values are reported in SWEDEHEART and therefore on admission assay results were not available in the dataset , the cardiac troponin concentration was not included.
A risk-score model was developed using the points system described by Sullivan et al 9 .
Briefly, as dichotomous variables were included in the model, each risk factor could take on the values 0 or ßi, where ßi represented the respective estimate of the regression coefficient of the multiple logistic-regression model. The regression coefficient of one of the variables was defined as the constant, B, which corresponded to one point in the point score. Each risk factor was assigned points by dividing ßi by B, rounded to the nearest integer. The estimated risk was determined by adding the intercept of the estimate, ß0, to the point total multiplied by the constant B and then transforming the sum using the logistic function. Model discrimination was assessed using the c-statistic and calibration by comparing observed to predicted risk in calibration plots.
Missing data
Complete data on all candidate variables (26) 
Internal validation
Since the number of events (n= 2077) was large relative to the number of predictors included in the final model, the risk of overfitting was considered to be negligible and bootstrapping of the sample not performed. This was further supported by using the heuristic shrinkage estimator of van Houewelingen and le Cessie with a computed estimated shrinkage factor of 0.997 10 .
Temporal validation A temporal validation was performed using data from SWEDEHEART between January 1
2005 and December 31 2007. This cohort (n=126 073, 102 762 unique patients) was selected using the same inclusion and exclusion criteria as for the derivation cohort. To adjust for missing data multiple imputation (20 imputed data sets) was performed in the same manner as for the original cohort.
External validation
External validation was undertaken using anonymised data from the Myocardial Ischaemia National Audit Project (MINAP) between January 1 2008 and December 31 2013. MINAP has been described in depth elsewhere 11 . In-hospital CA requiring defibrillation or cardiopulmonary resuscitation is recorded prospectively as part of MINAP. All analyses were conducted using a dichotomized variable defined as in-hospital CA "yes" or "no". The same inclusion and exclusion criteria as for the derivation cohort were used (supplementary figure 1 
Results
Derivation cohort
In total, 2077 (0.9%) cases of in-hospital CA were recorded in patients admitted to a hospital with suspected or confirmed NSTE-ACS in the derivation cohort (n=242 303). Patients with in-hospital CA were more likely to be older, have electrocardiographic ST-T-abnormalities, previous history of heart failure, and diabetes, lower systolic blood pressure, hemoglobin, and lower renal function (eGFR), higher heart rate and blood glucose level, and higher Killip class (table 1) .
Among patients with a final diagnosis of NSTE-ACS (n=102 650), there were 1.3% (n=1365) cases of in-hospital CA (supplementary figure 2 ). For patients with NSTE-ACS, invasive coronary treatment (PCI or CABG surgery) during index hospitalization was recorded for 581 (42.6%) cases with in-hospital CA and 53 063 (52.4%) cases without in-hospital CA. The majority of patients who were not diagnosed with ACS (n=139 653) had a final diagnosis of stable angina pectoris or non-cardiac chest pain (supplementary figure 3) . Among patients without ACS there were 0.5% (n=712) cases of in-hospital CA.
Derivation of the risk score
Five variables independently predicting in-hospital CA were included in the final risk score model. We developed a points score with a maximal sum of seven points whereby the included variables were: age ≥60 years (1 point), electrocardiographic ST-T abnormalities (2 points), Killip Class >1 (1 point), heart rate <50 or ≥100 bpm (1 point), and systolic blood pressure <100 mmHg (2 points) ( 
Discussion
Our study confirms that CA is a rare, yet not negligible complication following hospitalization for NSTE-ACS, affecting 1.3-2.3% of patients. For patients admitted with suspected NSTE-ACS, this study shows that the risk of in-hospital CA may be estimated using the SAFER score, consisting of five clinical findings (systolic blood pressure, age, heart rate, ECG changes, and heart failure signs) readily available on admission to hospital.
Discrimination of CA was good in the development and internal validation cohorts, though less so in the external validation cohort.
The CCU was introduced in the early 1960s, enabling patients with ACS to have continuous ECG monitoring where life-threating arrhythmias could be swiftly detected and treated by trained personnel 13 . With the development and improvement of care and outcomes for patients with ACS, questions have been raised about the need and cost effectiveness for lowrisk patients to be admitted to the CCU 14 . Current guidelines recommend that patients with non-ST elevation myocardial infarction and low risk for arrhythmias could be initially monitored in a CCU or an intermediate care unit likewise 5 . van Diepen and colleagues reported that in a population based cohort of nearly 8000 patients with stable NSTE-ACS, the majority of patients (65%) were admitted to a CCU but had no differences in clinical outcomes compared with those hospitalized in a cardiology telemetry ward (35%) 15 . The SAFER score could help the clinician select higher-risk patients that may benefit from monitoring in a CCU and lower-risk patients where monitoring in a cardiology telemetry ward may be sufficient.
The usefulness of this point score for excluding patients without need for rhythm monitoring is probably limited. In the SWEDEHEART cohort the risk of in-hospital CA rarely fell below 0.5% and in the MINAP cohort, patients with 1 risk score point had more than 1% risk of inhospital CA. However, equipment for heart rhythm monitoring is a scarce resource in many low-and middle-income countries 16 . In a limited resource setting, our point score could help decide who should be monitored. However, for any risk score model, it is important to consider the population under investigation and the underlying risk; application of the SAFER score to a different population would require an evaluation of underlying risk and external validation of the score.
We have not been able to evaluate the effect of the duration of cardiac monitoring, as the date and time of in-hospital CA was not recorded. However, in a study from Piccini and colleagues, patients with NSTE-ACS were as likely to have VT/VF after as before 48 hours and 38% had VT/VF after revascularization 2 . Therefore, a high-risk patient probably would benefit from extended monitoring and also here the SAFER score might aid in targeting patients.
Our findings are in concordance with a study by Goldman et al from 1996, which evaluated patients admitted with chest pain and the risk of in-hospital CA. Similar to our study, they found that five factors on admission (ST-segment elevation or Q-waves on initial ECG, ST-segment depression or T-wave inversion on initial ECG, systolic blood pressure below 110 mm Hg, pulmonary rales above the bases, and worsening of known ischemic heart disease)
were predictive of major in-hospital complications including CA 17 .
Although our study was based on a nationwide cohort of patients admitted with suspected NSTE-ACS, it has limitations. We were unable to differentiate between VT, VF and asystole/ pulseless electrical activity resulting in CA. There were missing data for in-hospital CA and CA prior to admission and for MINAP, Killip class was missing in a large proportion of patients, which could have decreased model discrimination. Data on timing of in-hospital CA
were not available and the temporal relationship to revascularization could not be assessed.
Notably, all study patients were admitted to a CCU because of suspected or confirmed NSTE-ACS and, therefore, patients with a final diagnosis of non-ACS cannot be compared to patients with undifferentiated chest patient in the emergency ward. This was particularly clear for the MINAP cohort, for whom non-ACS patients had an incidence of in-hospital CA equal to patients with NSTE-ACS.
Conclusion
We have shown that a simple risk score model, developed and validated in large national cohorts, including five easily accessible variables, predicts the risk of in-hospital CA for patients admitted with suspected NSTE-ACS and may help the clinician to choose proper level of surveillance. *defined as constant B; **estimated regression coefficient; ***Points= ßi / B rounded to the nearest integer; **** sum of (ß0 + point total x B) transformed with the logistic function
Conflicts of interest
None
